Title |
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors
|
---|---|
Published in |
Transplantation and Cellular Therapy, October 2015
|
DOI | 10.1016/j.bbmt.2015.10.005 |
Pubmed ID | |
Authors |
Mohamed Shanavas, Uday Popat, Laura C. Michaelis, Veena Fauble, Donal McLornan, Rebecca Klisovic, John Mascarenhas, Roni Tamari, Murat O. Arcasoy, James Davies, Usama Gergis, Oluchi C. Ukaegbu, Rammurti T. Kamble, John M. Storring, Navneet S. Majhail, Rizwan Romee, Srdan Verstovsek, Antonio Pagliuca, Sumithira Vasu, Brenda Ernst, Eshetu G. Atenafu, Ahmad Hanif, Richard Champlin, Paremeswaran Hari, Vikas Gupta |
Abstract |
The impact of JAK1/2 inhibitor therapy prior to allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort in myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes of patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 6 | 50% |
Canada | 2 | 17% |
Unknown | 4 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 50% |
Scientists | 3 | 25% |
Practitioners (doctors, other healthcare professionals) | 3 | 25% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 91 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 15 | 16% |
Researcher | 15 | 16% |
Student > Master | 8 | 9% |
Student > Postgraduate | 7 | 8% |
Student > Bachelor | 5 | 5% |
Other | 18 | 20% |
Unknown | 23 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 44 | 48% |
Biochemistry, Genetics and Molecular Biology | 5 | 5% |
Nursing and Health Professions | 3 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
Agricultural and Biological Sciences | 2 | 2% |
Other | 6 | 7% |
Unknown | 28 | 31% |